Extension Study of PRX-102 for up to 60 Months
NCT01981720
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
BIOLOGICAL:
PRX-102 (pegunigalsidase alfa)
Sponsor
Protalix
Collaborators
[object Object]